R
emarkable progress has been made in the implementation of continuous-flow left ventricular assist devices (CF LVADs) in moribund patients with refractory heart failure, with contemporary studies showing survival of 80% and 70% at 1 and 2 years, respectively. 1 However, device support remains fraught with hemocompatibility-related adverse events such as bleeding and thrombosis which account for nearly half of all adverse events (AEs). 2, 3 Device thrombosis (DT) and ischemic stroke occur despite antiplatelet therapy and anticoagulation with vitamin K antagonists, thereby prompting a need to further expand our understanding of contributory hematologic mechanisms and develop effective antithrombotic therapies.
The incidence of hemolytic events during durable CF LVAD support is estimated to be 15% to 35% and may affect as many as 1 in every 3 patients depending on the device type. [4] [5] [6] These hemolysis events have been defined by a rise in serum lactate dehydrogenase (LDH) levels to >2.5× the upper limit of normal (>700 U/L). 7 Prior investigations also show that LDH levels below this threshold, that is, low-level hemolysis (LLH), are present in HM II patients 3 to 4 weeks before DT and that the cause of DT is multifactorial with contributions from both mechanical and nonmechanical sources. [4] [5] [6] 8 Although conventional wisdom in the mechanical circulatory field has been that hemolysis is a result of thrombus obstructing blood flow, it is equally conceivable that a hemolysis-induced prothrombotic state may actually trigger and propagate thrombus formation. 4 Recently, it has been demonstrated that erythrocyte hemolysis, notably hemolysate with erythrocyte membrane fragments, and plasma free hemoglobin directly activate platelets leading to shape change and enhanced aggregation, with LDH being a marker rather than a mechanistic contributor. 9 Further, a causal role of hemolysis for the development of thrombosis has previously been established in diseases of intravascular hemolysis such as sickle cell anemia and paroxysmal nocturnal hemoglobinuria. 10 In these studies, it has been shown that extracellular free hemoglobin released from erythrocyte breakdown reduces nitric oxide (NO) bioavailability, thereby reducing intracellular cGMP generation and promoting platelet activation and aggregation (PA/A). [10] [11] [12] In this setting, prevention of cGMP breakdown with a phosphodiesterase-5 inhibitor, sildenafil, can reduce PA/A (Figure 1 ). 13 Similar to the aforementioned findings in patients with sickle cell anemia and paroxysmal nocturnal hemoglobinuria, in vitro studies have shown a dosedependent increase in PA/A with exposure of platelets to erythrocyte lysates and free hemoglobin in an LVAD model. 14 Because LLH is linked to subsequent thrombosis during CF LVAD support, we sought to investigate if concomitant use of sildenafil in patients on Heart Mate (HM) II support would impact PA/A and hematologic AEs.
METHODS

Study Population
All patients undergoing HM II implantation from January 2010 to December 2016 at Montefiore Medical Center were reviewed retrospectively. Only patients who survived to discharge were included in the study. All patients were on an a priori regimen of aspirin and were managed with warfarin to target an international normalized ratio (INR) of 2 to 3. We excluded patients receiving any antiplatelet agents other than aspirin, such as clopidogrel or dipyridamole. This investigation was approved by the Institutional Review Board at Montefiore Medical Center.
Clinical Data Collection
Baseline demographics and laboratory parameters at discharge were retrieved from medical charts. LLH was defined by a serum LDH 400 to 700 U/L (normal range in our laboratory is <280 U/L) at the time of discharge from the implant hospitalization. Patients were categorized into
WHAT IS NEW?
• Device thrombosis and stroke are major serious adverse events during continuous-flow left ventricular assist device support, yet their mechanisms and effective preventive strategies remain unknown.
• In this retrospective analysis, we observed that patients on Heart Mate II support with ongoing low-level hemolysis (LLH; lactate dehydrogenase: 400-700 U/L) have a significantly higher risk of subsequent device thrombosis or ischemic stroke. Concurrent sildenafil administration was associated with a reduction of this risk.
• Device thrombosis and ischemic stroke were associated with an increase in mean platelet volume, and patients with LLH not on sildenafil had a greater increase in mean platelet volume in comparison to those with LLH on sildenafil.
WHAT ARE THE CLINICAL IMPLICATIONS?
• These findings support a link between LLH and subsequent thrombosis and ischemic stroke on Heart Mate II support, and suggest a potentially protective role of sildenafil.
• On the basis of these hypothesis-generating data, mechanistic and prospective randomized studies are needed to explore the potentially beneficial role of therapies that enhance nitric oxide signaling to reduce platelet activation, such as sildenafil, when LLH is observed on continuous-flow mechanical circulatory support.
the following 4 groups: (1) LLH not on sildenafil, (2) LLH on sildenafil, (3) no LLH not on sildenafil, and (4) no LLH on sildenafil. Patients were on sildenafil for at least 30 days after discharge from the implant hospitalization for either right ventricular dysfunction or pulmonary hypertension. Thrombosis outcomes, including DT and ischemic stroke, were retrieved for ≤365 days after discharge from the implant hospitalization. Hemorrhagic outcomes, including major gastrointestinal bleeding and intracranial hemorrhage, were also retrieved. INR was collected in monthly intervals for the duration of the study period and at the time of AEs. LDH and mean platelet volume (MPV), a potentially surrogate biomarker of PA/A, 15 were also collected over time.
Definition of AEs
DT was defined as a major device-related malfunction in which thrombus was confirmed within the blood contacting surfaces of the device. All device thromboses were confirmed by direct inspection and visualization after removal of the device. Ischemic stroke was defined by the presence of an acute cerebral infarction noted on a head computed tomographic scan and accompanied by neurological symptoms. Major gastrointestinal bleeding was defined by requiring a blood transfusion and a drop in hemoglobin of >2 g/dL. Intracranial hemorrhage was confirmed on head computed tomographic scan and accompanied by neurological symptoms.
Data Analysis
The primary end point was freedom from any thrombotic event. A separate analysis was conducted to assess survival free from a hemorrhagic event. Survival analyses are based on the time to the first hematologic AE. Subsequent AEs were excluded because those may have occurred during altered antithrombotic regimens.
Statistical Analysis
Data are displayed as mean±SD, unless otherwise indicated. Baseline demographics were compared between patients in all 4 groups by the ANOVA test for continuous variables and by the χ 2 test for categorical variables. Student paired t test was used to compare differences in MPV at discharge and at the time of DT or ischemic stroke. Repeated measures of LDH, INR, and change in MPV during HM II support were compared between groups by applying linear mixed-effects modeling. Cumulative survival free from thrombotic and hemorrhagic events at 365 days after discharge from the implant hospitalization was shown using Kaplan-Meier curves which are censored for heart transplantation, HM II explantation, and death. A logrank P value was generated which represents the probability of differences between group across the entire study period. Hazard ratios (HRs) were calculated using Cox proportional hazards analyses. Multivariable analysis was done for thrombotic and hemorrhagic events with adjustment for variables that have been shown to be associated with such AEs in previous Lactate dehydrogenase (LDH) is a biomarker released from the breakdown of erythrocytes during hemolysis. Extracellular free hemoglobin is also released during hemolysis which scavenges nitric oxide (NO) by reducing it to nitrate. Under normal conditions, NO diffuses into platelets to stimulate guanylyl cyclase (GC) to produce cGMP. cGMP activates G kinase. G kinase in turn phosphorylates the thromboxane (TXA 2 ) receptor on platelet membranes, which disrupts coupling of this receptor to its GTPbinding protein, G q , to inhibit activation of effector phospholipase C, thereby preventing Ca 2+ mobilization and platelet activation and aggregation (PA/A). Under hemolysis conditions, this inhibitory pathway for PA/A can be suppressed by a free hemoglobininduced NO deficiency. In this setting, sildenafil, which inhibits phosphodiesterase-5 (PDE-5) to prevent the breakdown of cGMP, may reactivate the preceding inhibitory for PA/A. iCVA indicates ischemic cerebrovascular accident; and RBC, red blood cell.
investigations, including age and sex. P values of ≤0.05 were considered statistically significant. Statistical analyses were conducted using the SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
Patient Characteristics
The study group comprised 144 patients who were supported by an HM II and met the inclusion criteria. The mean age was 50±13 years, and 35 (24%) patients were women. Ninety-three (65%) patients had a history of hypertension, and 89 (62%) had diabetes mellitus. Table 1 shows that no differences were present in major demographics, laboratory parameters, pump parameters, and aortic valve opening at discharge across all 4 groups. Thirty-one patients had LLH with a discharge LDH of 512±98 U/L and were not on sildenafil, whereas 16 patients had LLH with a discharge LDH level of 473±79 U/L and were on sildenafil (P=0.45). LDH remained elevated over time in patients with LLH (P<0.001 versus no LLH; Figure 2 ). No LLH was present in 76 patients (discharge LDH: 292±59 U/L) not on sildenafil and 21 patients (discharge LDH: 289±52 U/L) on sildenafil. INR during the entire HM II support period was similar across all 4 groups (P=0.84; Figure 3 ), and the INR at the time of AEs was also similar between groups as shown in Table 2 .
Sildenafil Usage
Sixteen patients with LLH were on sildenafil (8 for right ventricular dysfunction and 8 for pulmonary hypertension). The mean dose of sildenafil in patients with LLH was 29±13 mg every 8 hours. Twenty-one patients without LLH were on sildenafil (15 for right ventricular dysfunction and 6 for pulmonary hypertension). The mean dose of sildenafil in patients without LLH was 34±15 mg every 8 hours. Patients remained on sildenafil for the duration of the study period. Two patients (1 with LLH and 1 with no LLH) reported dizziness and headache after 48 and 145 days of followup, respectively, and were taken off sildenafil. Both patients were censored from the study at the time of sildenafil cessation.
Rates and Likelihood of Thrombotic and Hemorrhagic AEs
Overall, 17 of 144 (12%) patients had thrombotic events over a total support period of 94.6 years. The average time to a thrombotic event was 187±107 days. Twelve (8%) had DT, and 5 (3%) experienced an ischemic stroke. Thirty-two (23%) had hemorrhagic events, including 26 (18%) with a gastrointestinal bleeding and 6 (4%) experiencing an intracranial hemorrhage. Three patients had gastrointestinal bleeding before discharge and were excluded from further follow-up of hemorrhagic events.
Proportionately, more patients with LLH not on sildenafil had thrombotic events (39%) in comparison to those with LLH on sildenafil (6.3%), those without LLH on sildenafil (4.7%), and those without LLH not on sildenafil (3.9%; Table 2 ). For the entire follow-up period, survival free from thrombotic events was significantly lower in patients with LLH not on sildenafil, in comparison to those with LLH on sildenafil and to those without LLH off and on sildenafil (P<0.001, Figure 4A ). All groups had a similar INR at the time of the event (Table 2) . Specifically, more DT occurred in patients with LLH not on sildenafil (23%) in comparison to those with LLH on sildenafil (6.3%). Only patients with LLH not on sildenafil had an ischemic stroke (16%). Consequently, patients with LLH not on sildenafil had a higher adjusted HR (aHR) of 15 (95% confidence interval, 4.5-50; P<0.001; All groups had similar freedom from hemorrhagic events during the study period (P=0.64; Figure 4B ). Moreover, in comparison to patients with no LLH not on sildenafil, all groups had a similar likelihood of experiencing a hemorrhagic event (Table 3) .
MPV and Thrombosis
At discharge, the MPV was similar between groups as shown in Table 1 . The MPV rose significantly in patients with thrombotic events from 9.6±0.5 to 10.9±0.8 fL (P=0.00002; Figure 5 ). On longitudinal monitoring, beginning at 1 month after discharge from the implant Figure 6 ).
DISCUSSION
We investigated the association of sildenafil administration, MPV, and hemocompatibility-related adverse events in patients with LLH during HM II support. Our principal findings are as follows: first, LLH during HM II support is associated with an increased frequency of thrombotic events. Second, use of sildenafil in this setting was associated with a reduced likelihood of thrombotic events. Third, MPV, which may be a marker of PA/A, increases during LLH and particularly leading up to thrombotic events, but this increase was not seen with concomitant sildenafil administration. Last, the lower rate of thrombotic events with ongoing LLH on sildenafil was not offset by higher hemorrhagic events which were not significantly different across all groups. These findings are not likely to be confounded by a variation in anticoagulation because there were no differences in the INR across groups at the time of AEs or during HM II support. In addition, longitudinal LDH monitoring showed that differences in LLH between groups, initially stratified at discharge, persisted for the entirety of the study period.
To our knowledge, this is the first report to assess the association of sildenafil therapy in limiting thrombotic events during LLH in patients on HM II support. MPV is a marker of platelet activation as larger platelets contain more dense granules which produce more thromboxane A 2 . 16 Higher MPV has been associated with greater in vitro platelet aggregation in response to adenosine diphosphate and collagen. 16 Importantly, increased MPV is closely linked to subsequent thrombosis including myocardial infarction and ischemic stroke in the general population. [17] [18] [19] We observed that HM II patients with LLH not on sildenafil had a greater increase in MPV in comparison to those with LLH on sildenafil as early as 1 month after discharge and that the former patients had the highest rate of thrombotic events. Such observed effects could be related to the antiplatelet effects of sildenafil under hemolytic conditions.
Within platelets, NO activates guanylate cyclase producing cGMP and activating G kinase. G kinase in turn phosphorylates the thromboxane receptor on platelet membranes, which disrupts coupling of this receptor to its GTP-binding protein, G q , to inhibit activation of effector phospholipase C, thereby preventing Ca 2+ mobilization and PA/A. 20 By the preceding mechanism, NO represses PA/A; however, with ongoing hemolysis, extracellular free hemoglobin directly reduces NO bioavailability by oxidizing it to nitrate. 10 When NO bioavailability is reduced during ongoing hemolysis, the propensity of PA/A is increased, further driving thrombus formation. 21 Consistent with this model, we speculate that with ongoing LLH during HM II support, there is reduced NO bioavailability leading to greater PA/A. In this setting, sildenafil, which potentiates NO signaling by inhibiting phosphodiesterase-5 to prevent breakdown of cGMP, could decrease PA/A to limit thrombus formation (Figure 1 ). Our findings of reduced thrombotic events in patients with LLH on sildenafil are consistent with this hypothesis.
At this time, the cornerstone of antiplatelet therapy during CF LVAD support is aspirin. However, prior investigations have observed no differences in the platelet activation state with or without aspirin during CF LVAD support. 22 Thus, during hemolysis conditions, which may augment platelet function, further consideration may need to be given to pharmacological agents that enhance NO signaling to suppress platelet function.
Although the incidence of hemolysis varies by device type and may be further reduced by evolution of device design to attain greater hemocompatibility, it remains universally prevalent in both durable and acute support CF mechanical circulatory field devices. Free hemoglobin has been associated with poor survival in patients on extracorporeal membrane oxygenation, 23 and hemolysis is very common during Impella support. 24 Further prospective mechanistic and clinical studies to elucidate the impact of hemolysis on augmenting PA/A and its reversal by NO enhancing therapies such as sildenafil may limit devastating thrombotic complications.
This investigation has several limitations. Foremost, this study is limited by a retrospective design that can lead to information bias, which may arise if not all AEs were appropriately documented correctly in medical charts. To ensure accuracy, we verified all AEs by cross-referencing them with concurrent radiological and endoscopic studies. Because of a relatively low number of AEs and to maintain the validity of the multivariable model, adjustment was not feasible for all covariables that may impact AEs. Although there were no visible differences among the major demographics and discharge laboratory parameters across study groups, there may be intrinsic and nonapparent differences in patients with pulmonary hypertension and right ventricular dysfunction who received sildenafil, which are protective against thrombosis. Although it is conceivable that even LLH could be a result of an early microthrombus at discharge, the findings still implicate its role in propagation to clinical thrombotic events, which were noted to be lower with concomitant sildenafil. Because of a small overall number of thrombotic events, there is inherently low precision and low power to detect intergroup differences in hazards which may be unique to our institution. Therefore, the reported findings need to be further confirmed in larger multicenter populations with potentially greater numbers of thrombotic events. It is important to underscore that the observed findings were noted in patients with LLH categorized at discharge. The impact of sildenafil on those patients who present with overt hemolysis from a consequence of thrombosis is unknown. Because the average lifespan of a platelet is 8 to 10 days, 16, 18 it is unlikely that the MPV measure at the time of the thrombotic event was affected by the event itself. We were unable to use plasma free hemoglobin to stratify groups because of significant day-to-day variations in this assay at our institution. Sildenafil usage may be associated with adverse effects, and these have been listed from the package insert in Table I in the Data Supplement.
In conclusion, our data show that with ongoing LLH, sildenafil usage is associated with reduced DT and ischemic stroke during HM II support. This reduction in thrombosis may be related to a lower PA/A. To explore this association, randomized mechanistic studies in CF mechanical circulatory field recipients with LLH are warranted.
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